• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 430642 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416982009 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416982009 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of Acadia Pharmaceuticals Rise Above Previous 52-Week High

Published on Mon, 01/28/2013 - 15:11
By Peter Chu

Acadia Pharmaceuticals (NASDAQ:ACAD) traded at a new 52-week high today of $6.67. Approximately 6.4 million shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares.

In the past 52 weeks, shares of Acadia Pharmaceuticals have traded between a low of $1.29 and a high of $6.67 and are now at $6.62, which is 413% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 7.0% while the 200-day MA has risen 3.4%.

Potential upside of 26.2% exists for Acadia Pharmaceuticals, based on a current level of $6.62 and analysts' average consensus price target of $8.36. The stock should discover initial support at its 50-day moving average (MA) of $4.48 and subsequent support at its 200-day MA of $2.48.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Shares of Ventas Rise Above Previous 52-...

Ventas (NYSE:VTR) traded today at a new 52-week high of $70.11. So far today approxima ...

Shares of Validus Holdings Rise to a New...

Shares of Validus Holdings (NYSE:VR) traded at a new 52-week high today of $41.42. So ...

Watch for Continued Gains in Shares of V...

Shares of VF Corp (NYSE:VFC) traded today at $74.38, breaking its 52-week high. This n ...

Shares of Valspar Have Risen Above Previ...

Valspar (NYSE:VAL) traded at a new 52-week high today of $87.59. Approximately 849,000 ...

Visa: The Winning Streak Continues (V)...

Visa (NYSE:V) traded today at a new 52-week high of $258.00. So far today approximatel ...

Union Pacific Looks to Continue to Trade...

Union Pacific (NYSE:UNP) traded today at a new 52-week high of $123.61. This new high ...

Shares of Textron Have Risen Above Previ...

Textron (NYSE:TXT) traded at a new 52-week high today of $44.47. This new high was rea ...

Shares of Take-Two Interactive Software ...

Take-Two Interactive Software (NASDAQ:TTWO) traded today at a new 52-week high of $28.0 ...